Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Journal of Viral Hepatitis

Volumn 10, Issue 6, 2003, Pages 460-466

  Van Vlierberghe, H ^a   Leroux Roels, G ^a   Adler, M ^b   Bourgeois, N ^b   Nevens, F ^c   Horsmans, Y ^d   Brouwer, J ^e   Colle, I ^a   Delwaide, J ^f   Brenard, R ^d   Bastens, B ^g   Henrion, J ^h   De Vries, R A ^k   De Galocsy, C ⁱ   Michielsen, P ^j   Robaeys, G ^k   Bruckers, L ^l  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CHU SART TILMAN   (Belgium)

^g Department of Gastroenterology   (Netherlands)

^h Hospital de Jolimont   (Belgium)

ⁱ Cliniques St Anne St Remy   (Belgium)

^j ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^k AZ St Jan ^*

^l Centre for Statistics   (Belgium)

more..

Author keywords

Hepatitis C virus; Induction; Interferon alpha 2b; Ribavirin; Treatment

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; END OF TREATMENT RESPONSE; FEMALE; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED RESPONSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BELGIUM; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MIDDLE AGED; NETHERLANDS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 10744229401     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00466.x     Document Type: Article

References (24)

1. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 31(Suppl 1): 3-8.
2. Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. Effect if interferon alfa on the dynamics of hepatitis C turnover in vivo. Hepatology 1996; 23: 366-371.
3. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-107.
4. Zeuzem S. Favourable and disappointing lessons from viral kinetics. J Hepatol 2002; 37: 151-153.
5. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
6. Zeuzem S, Lee JH, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156.
7. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa 2a. Gastroenterology 2001; 120: 1438-1447.
8. Gnomon AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:28-35.
9. Di Marco V, Ferraro D, Almasio P et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepatitis 2002; 9: 354-359.
10. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33(2): 419-423.
11. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
12. McHuntchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
13. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28(6): 960-964.
14. Neumann AU, Dahari H, Conrad A, Planko S, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN alpha dual therapy effect on chronic hepatitis C. Hepatology 1999; 30: 309A.
15. Pawlotsky JM, Dahari H, Conrad A et al. Effect of intermittent interferon, daily IFN and IFN plus ribavirin induction therapy of hepatitis C virus genotype 1b replication kinetics and clearance. Hepatology 1998; 28: 288A.
16. Zeuzem Z, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252.
17. Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U. Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha treated patients with response or no response. Z Gastroenterol 2000; 38: 881-886.
18. Fried MW, Shiffman M, Sterling RK et al. A multicenter, randomized trial of daily high-dose interferon alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95: 3225-3229.
19. Layden TJ, Layden JE, Rajender Reddy K, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon does not improve sustained virological response in chronic hepatitis C. J Viral Hepatitis 2002; 9: 334-339.
20. Poynard T, Daurat V, Chevret S et al. A short induction regimen of interferon alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. J Viral Hepatitis 1999; 6: 381-386.
21. Ferenci P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
22. Carithers RL, Zeuzem S, Manns MP et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa 2b plus ribavirin. Hepatology 2000; 32: 317A.
23. Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roels G and the BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 911-916.
24. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.